Europe already has the biotech machinery. It hasn’t scaled it

EU PERSPECTIVES - Europe is not short on biotech talent or science. But while the EU designs strategies, competitors are already moving faster, warns Dr Montse Daban of the Council of European BioRegions. She argues that Europe's real problem is fragmentation — and that the upcoming Biotech Act will stand or fall on execution rather than ambition. Read more

Interview with Dr. Montse Daban, President of the Council of European BioRegions (CEBR)